Figure 1 (Crysvita 01)
Crysvita Injection
Product Images NDC 42747-102
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Crysvita (NDC 42747-102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Kyowa Kirin, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Crysvita 02)
This appears to be a graph or chart depicting the results of a clinical trial involving a drug called CRYSVITA. The graph shows the serum phosphorus levels of participants during a double-blinded period and an open-label period. Placebo and CRYSVITA were both used in the trial, with CRYSVITA showing an improvement in serum phosphorus levels compared to the placebo group. However, without more context or information about the trial, it's difficult to provide a full description of the results.*
Figure 3 (Crysvita 03)
Principal Display Panel (10 mg/mL Vial Carton)
This appears to be a label of a medication called CRYSVITA, produced by Kyowa Kirn Inc. It is a 1.5 mL 1" Disposable Unised Perinjectonsite, intended for subcutaneous use only. The medication contains 10 mg of Burosumab-Twza, a potency drug, and must be refrigerated when stored. The label also contains an NDC number, which could be used for identification and tracking purposes.*
Principal Display Panel (30 mg/mL Vial Carton)
This is a medication label. The name of the medication is CRYSVITA made by AN and manufactured in Princeton, NJ. The medication is administered via subcutaneous injection and must be refrigerated. The Polysorbate 80 and Burosumab-twza are some of the ingredients. The single-dose vial should be discarded once 1.5 mL volume has been used, and the unused portion should be discarded as well. NDC ID is 42747-304-01.*
Principal Display Panel (20 mg/mL Vial Carton)
Principal Display Panel (10 mg/mL Vial)
C RYSVITA® is a medication available in the form of a single-dose vial injection containing 10 mg/mL of burosumab-twza. It is manufactured by Kyowa Kirin, Inc. and its NDC number is 42747-102-01. The medication is used to treat a rare genetic disorder called X-linked hypophosphatemia (XLH).*
Principal Display Panel (20 mg/mL Vial)
This appears to be a description of a pharmaceutical product. The product name is CRYSTALTA, with the National Drug Code 42747-203-01. It comes in a single-dose vial of 1 mL and is given by injection. The manufacturer is Kyowa Kirin, Inc. The product has a lot number and an expiry date, but these are illegible in the provided text.*
Principal Display Panel (30 mg/mL Vial)
This is a description of a medication called "burosumab-twza". It comes in a 1 mL vial as an injection with a concentration of 0 mg/mL produced by Kyowa Kirin, Inc. There is a U.S. license number and an expiration date indicated. The rest of the text is not clear and appears to be incomplete or illegible.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
